Antimicrobial prophylaxis for primary immunodeficiencies
Alexandra F. Freeman and Steven M. Holland

Purpose of review
Antibiotic prophylaxis is one of the mainstays of therapy of primary immunodeficiencies. We aim to summarize what is known about antibiotic prophylaxis for select primary immunodeficiencies.

Recent findings
In recent years, there has been a push towards more evidence-based practices for antimicrobial prophylaxis for many conditions such as antifungal prophylaxis for extremely premature neonates and antibiotic prophylaxis for neutropenia associated with chemotherapy. However, there are remarkably few data regarding antibiotic prophylaxis in primary immunodeficiencies and regimens vary greatly between practices.

Summary
Currently, antibiotic prophylaxis is guided by the common microbial pathogens seen in specific immunodeficiencies, and experience with other chronic illnesses such as cystic fibrosis, HIV, and immunosuppression from transplantation. Controlled studies are necessary to address the preferred antimicrobial and immunomodulator regimens for most of the primary immunodeficiencies.

Keywords
antibiotic prophylaxis, humoral defects, hyper-IgE syndrome, neutrophil defects, primary immunodeficiencies

Introduction
The HIV pandemic – an immune deficiency associated with discrete infections – spawned multiple prospective, well-designed, robustly powered studies [1]. However, antimicrobial prophylaxis for the majority of other well-studied conditions has rarely been studied in depth, let alone prospectively in a well-powered way. Therefore, antimicrobial prophylaxis has been driven for years by clinical beliefs and clinical anxiety, but without much in the way of data-driven guidelines. Recently, some of the standard prophylactic practices have been questioned, along with the movement towards evidence-based practices. For example, there has been a recent marked decrease in the indications for endocarditis prophylaxis [2]. There has also been a reassessment of prophylactic antibiotics in vesicoureteral reflux [3], and some push away from prophylactic antibiotics for otherwise healthy children with recurrent otitis due to concerns of antimicrobial resistance [4]. In contrast, in other patient populations, there has been increasing evidence for prophylaxis including antifungals for extremely premature infants [5], and prophylactic antibiotics (typically a fluorquinolone) during neutropenia associated with high-risk chemotherapy [6]. Importantly, in these studies the emergence of resistant organisms has been minimal.

Despite the well recognized role of infections in primary immunodeficiencies and the wide conviction that they should be prevented with prophylactic antibiotics, there is a real dearth of evidence-based practices leading to marked variation between groups [7]. Therefore, in this review we will discuss antibiotic management and prophylaxis guided by the common infecting organisms in select primary immunodeficiencies.

Neutrophil defects
Chronic granulomatous disease (CGD) is characterized by an abnormal neutrophil respiratory burst due to defects of the NADPH oxidase, resulting in impaired neutrophil killing of select bacteria and fungi. Children with CGD usually present within the first few years of life with recurrent bacterial or fungal infections or tissue granuloma formation [8]. Typical pathogens in CGD patients are Staphylococcus aureus, Nocardia species, Ser- rataea marcescens, Burkholderia cepacia, and Aspergillus species. Less frequent pathogens include other molds, other Gram-negative bacteria, and mycobacteria. Standard prophylactic treatment of CGD consists of a combination of antibiotics, antifungals, and interferon (IFN)-gamma [9]. Bone marrow transplantation can be curative.
Chronic granulomatous disease is one of the few primary immunodeficiencies for which antimicrobial prophylaxis has been systemically studied. Trimethoprim-sulfamethoxazole (TMP-SMX, 6 mg/kg/day of trimethoprim divided twice daily) is the ideal antibacterial prophylactic agent as it has good activity against the most common bacterial pathogens of CGD, including *Nocardiia* and community-acquired Methicillin-resistant *S. aureus* (MRSA) [9]. Studies have shown a decrease in bacterial infections in CGD while on TMP-SMX therapy from about one infection per year to about one every 4 years [10,11]. With the exception of *S. aureus*, the pathogens of CGD are environmental and not commensals of humans; therefore, antimicrobial resistance is rare. The best antimicrobial for individuals with TMP-SMX allergy or intolerance is unclear. TMP-SMX desensitization should be considered when feasible. Second or third-generation cephalosporins can prevent most of the Gram-negative and methicillin-sensitive *S. aureus* infections. However, with increasing antibiotic resistance in community-circulating strains, this therapy may have limitations, and *Nocardiia* may not be covered. Fluoroquinolones provide Gram-negative, and some *S. aureus* and *Nocardiia* coverage; but toxoplasmosis, including arthralgias and tendonitis and hypothetical concerns regarding long-term use in children may limit utility.

Until recently fungal infections were the leading cause of mortality in CGD. A placebo-controlled cross-over study of itraconazole prophylaxis showed marked efficacy against fungal infections in CGD [12]. Of the 39 enrolled patients, seven developed fungal infections while on placebo, whereas only one developed a fungal infection while on treatment. Plasma levels were checked due to the poor absorption of itraconazole in capsule form. Infections were prevented despite low plasma levels, suggesting that subtherapeutic or intermittent levels are effective for prophylaxis or that the critical prophylactic moiety is not properly measured as either itraconazole or dihydroitracaconazole. At any rate, routine monitoring of levels during prophylaxis is not indicated. In the last several years, the use of oral voriconazole and posaconazole has increased. These antifungals have not been studied for prophylaxis in CGD, but likely have efficacy similar, if not better than itraconazole, as their spectrum of fungal coverage is broader and their absorption is better. Voriconazole and posaconazole prevent invasive mold infections in hematopoietic stem cell transplant populations [13]. Long-term therapy with voriconazole may be hindered by photosensitivity or hepatotoxicity; adherence to posaconazole may be hindered by its liquid formulation.

Less is known about antibiotics for the less common neutrophil defects. Leukocyte adhesion deficiency (LAD)-1 is characterized by delayed umbilical stump separation and omphalitis, severe gingivitis and periodontitis, skin infections with necrotic ulcerative lesions, and respiratory infections [14,15]. Pathogens in LAD-1 include *S. aureus*, Gram negatives, and oral flora, but not fungi. For those LAD-1 patients not transplanted, prophylactic antibiotics are typically used. Coverage of Gram negatives, oral flora and *S. aureus* should be considered. If MRSA is not present, amoxicillin/clavulanate or fluoroquinolones are reasonable. For other phagocytic defects, such as Cheviak-Higashi and Griscelli syndromes, characterized by recurrent pyogenic infections, prophylactic therapy is typically individualized to the patient’s infections.

**Humoral immunodeficiencies**

Humoral immunodeficiencies are characterized by chronic or recurrent ear, sinus, and lung infections predominantly with encapsulated bacteria such as *Streptococcus pneumoniae* and *Haemophilus influenzae* [16]. There is a spectrum of antibody deficiency included in this class, from the total absence of B cells and immunoglobulins in X-linked agammaglobulinemia (XLA), to the later presentations with more granulomatous complications in common variable immune deficiency (CVID). These immunodeficiencies are treated with replacement immunoglobulin. Use of prophylactic antibiotics varies widely, especially in CVID [17]. Some practitioners add prophylactic antibiotics if recurrent infections exceed three per year while on IVIG or if any severe infections occur [18]; others provide prophylactic antibiotics to all individuals with severe antibody deficiencies on IVIG, whereas yet others only treat acute infections for individuals on IVIG. These variations in practice reflect the lack of controlled studies of prophylactic antibiotics in primary antibody deficiency disorders. Studies of prophylactic antibiotics decrease the number of otitis media recurrences in presumably immunocompetent children [19,20]. These studies used predominantly TMP-SMX or amoxicillin, both of which cover the predominant sinopulmonary pathogens, and suggest these may be appropriate choices for sinopulmonary infections from encapsulated bacteria [16]. Consistent use of one antibiotic is typically effective and associated with less resistance than the unsubstantiated practice of cycling antibiotics.

Although sinopulmonary infections predominate in humoral immunodeficiencies, XLA may be associated with neutropenia, leading to more serious staphylococcal or *Pseudomonas* infections; the neutropenia often resolves after IVIG replacement [16]. Giardia, mycoplasma and ureaplasma infections also occur in XLA, as well as persistent bacteremia and skin infections with *Helicobacter*-like organisms. Typically, prophylaxis for these organisms is not given, but accurate diagnosis and treatment are required. Chronic mycoplasma infections require prolonged treatment. Severe meningococcal enteroviral infections are best prevented by maintenance of good replacement IVIG levels.
Individuals with CD40 ligand (CD40L) deficiency (X-linked hyper IgM syndrome), the most common of the immunoglobulin class switch defects, are predisposed to pyogenic sinopulmonary infections similar to those seen in XLA and successfully treated with immune globulin replacement. However, CD40L deficiency T cell defects predispose to Pneumocystis jiroveci (PCP), Cytomegalovirus (CMV), toxoplasmosis and sclerosing cholangitis [16]. Therefore, PCP prophylaxis is necessary, making TMP-SMX useful for PCP and pyogenic infection prevention. Avoidance of opportunistic fungi, avoidance of fungal fungemia, and nontuberculous mycobacteria, are infrequent in antibody deficiency-associated bronchiectasis, but careful microbiologic evaluation is necessary during pulmonary exacerbations [18].

Azithromycin may improve lung function and decrease pulmonary exacerbations in both CF and non-CF bronchiectasis through its anti-inflammatory actions [21,22]. Although studies have not looked specifically at antibody deficiency, individuals with bronchiectasis and recurrent pulmonary exacerbations despite adequate immune globulin replacement may benefit from azithromycin, which is also active against mycoplasma.

For individuals with bronchiectasis and Pseudomonas colonization, inhaled antibiotics may be considered. In the US, the most experience is with inhaled tobramycin in CF resulting in improved pulmonary function, decreased bacterial load, and decreased hospitalizations [23]. In non-CF bronchiectasis, inhaled antibiotics may decrease the number of hospitalizations and microbial load, but not necessarily improve pulmonary function [23–26]. Intolerance of inhaled tobramycin frequently manifests as bronchospasm or hoarseness. Although acquired antimicrobial resistance has been demonstrated in some pathogens, no studies of inhaled antibiotics have focused specifically on primary immunodeficiencies.

**Primary T cell immunodeficiencies**

Severe combined immunodeficiency (SCID) arises from a growing list of genetic defects that cause severe deficiencies of number and/or function of T, B, and natural killer (NK) cells. SCID typically presents in the first few months of life with failure to thrive and recurrent viral, bacterial and candida infections resulting in death within the first year of life without definitive treatment [27]. Optimal management depends on early diagnosis and aggressive treatment and prevention of infections. Improved outcomes correlate with earlier diagnosis and definitive treatment, most commonly stem cell transplantation. Prophylaxis while awaiting definitive treatment is aimed at PCP (TMP-SMX) and immune globulin replacement. Fluconazole is frequently given to prevent mucocutaneous candidiasis and acyclovir to prevent herpes virus infection. If infections such as CMV are present, treatment should continue until definitive treatment (i.e. transplant) is performed. When BCG vaccination has been performed treatment should be given; nontuberculous mycobacteria (NTM) infections do not occur in SCID, so NTM prophylaxis is typically not needed. Live vaccines should be avoided, and all blood products should be CMV-negative and irradiated, or if not possible, leukocyte-depleted to minimize CMV transmission. Breast milk can transmit CMV, and some centers discourage breastfeeding until the CMV status of the mother is known.

DiGeorge syndrome is characterized by some combination of the following characteristics: immune dysfunction secondary to thymic hypoplasia, congenital heart defects, palatal abnormalities, hypocalcemia, characteristic facies and learning difficulties. The degree of immune dysfunction is variable and relates to the degree of impaired T cell development, although not necessarily the size of the thymus [28]: humoral defects are atypical. In severe thymic aplasia and profound T cell lymphopenia, which occur in less than 1% of DiGeorge cases, reprogramming of T cells through thymus transplant can be performed. However, for the majority of DiGeorge cases, immunodeficiency is not severe, may improve with age, and prophylactic antibiotics are often not necessary. Fewer opportunistic infections are seen in DiGeorge syndrome than in individuals with similar T cell numbers who have HIV. Most infections are upper respiratory tract infections, and may be due in part to structural abnormalities associated with the syndrome. Live viral vaccination should be avoided for individuals with severe T cell lymphopenia, but vaccination is recommended for those with more mild defects [29].

**Hyper IgE syndrome**

Autosomal dominant hyper IgE (Job’s) syndrome (STAT3-deficient HIES) is characterized by S. aureus susceptibility with recurrent skin and lung infections, and a S. aureus-driven eczematoid rash [30]. Other pulmonary pathogens include pyogenic bacteria such as S. pneumoniae and H. influenzae. PCP may be the presenting pulmonary
infection, but is rare outside of infancy. Healing of pneumonias is often abnormal and bronchiectasis and pneumatoceles may result, which are then sources of Gram-negative chronic infections (typically *Pseudomonas aeruginosa*), molds (Aspergillus and Scedosporium), or nontuberculous mycobacteria. Recurrent ear and sinus infections and mucocutaneous candidiasis are common. Infrequent but severe infections include extrapulmonary histoplasmosis, cryptococcosis, and coccidioidomycosis.

With the increasing frequency of community-acquired MRSA sensitive to TMP-SMX and the occurrence of PCP, TMP-SMX is an ideal prophylactic antibiotic for HIES. It is typically dosed at about 6 mg/kg/day of the TMP portion divided twice daily. With consistent adherence to this regimen, bacterial resistance is rare. Breakthrough infections should be cultured and therapy adjusted accordingly. Cycling of antibiotics has no advantage over use of one antibiotic consistently, and may lead to more resistance. Eczema driven by *S. aureus* may still occur despite appropriate antibiotics and responds quite well to dilute bleach baths (125 ml commercial bleach in a tub of water 15 min three times weekly) or frequent swimming in chlorinated pools.

The morbidity and mortality of HIES are typically associated with the structural lung defects that result after pyogenic bacterial infections. When bronchiectasis develops, colonizing organisms are similar to those of CF, with *Pseudomonas* predominating and eradication difficult. Nontuberculous mycobacteria and molds are also seen. Aspergillomas often develop in pneumatoceles and may lead to vascular invasion with life-threatening hemoptysis or dissemination [31]. Therapy must be tailored to the colonizing species. Long-term therapy for fluoroquinolone-sensitive *P. aeruginosa* appears beneficial, but chronic toxicities from fluoroquinolones need to be considered. Azithromycin and inhaled tobramycin may be considered in bronchiectasis. If azithromycin is to be used, pulmonary nontuberculous mycobacterial infection should be excluded before inadvertent initiation of monotherapy. Inhaled tobramycin can cause airway irritation leading to bronchospasm and hemoptysis.

Mucocutaneous candidiasis and onychomycosis respond rapidly to fluconazole. *Aspergillus* associated with structural lung abnormalities in HIES are more worrisome and less well studied. Itraconazole prevents *Aspergillus* lung infections in CGD [12], whereas posaconazole and voriconazole have been shown to work in hematopoietic stem cell transplant recipients [13]. In CGD and transplantation, however, the mold infections are parenchymal and invade structurally normal lung; mold infections in HIES occur in pneumatoceles and bronchiectasis. A similar anatomy is seen in CF patients, who are at risk for allergic bronchopulmonary aspergillosis (ABPA). In ABPA, antiaspergillus azoles including itraconazole and voriconazole may improve symptoms and decrease exacerbations [32,33]. Lung transplant recipients also have increased risk of pulmonary aspergillosis and airway colonization. Voriconazole decreased invasive *Aspergillus* infections after lung transplant, although not necessarily *Aspergillus* colonization [34]. Also, inhaled amphotericin B can prevent invasive *Aspergillus* in lung transplant recipients [35], but the period of greatest risk for pulmonary aspergillosis is relatively short and thus treatment is for a finite time. Inhaled amphotericin may cause cough and increased irritation and may exacerbate hemoptysis. We typically treat individuals with *Aspergillus* infection with posaconazole due to its good long-term tolerability; however, eradication of *Aspergillus* infection and colonization in HIES is infrequent. For high-risk patients with significant structural lung disease we consider antifungal prophylaxis, typically with itraconazole or posaconazole.

### Defects predisposing to disseminated nontuberculous mycobacterial infection:
### IL-12/IFN-gamma axis and NF-kB essential modulator

Defects of the IL-12/IFN-gamma axis predispose to NTM infections, as well as *Salmonella* and the endemic mycoses *Histoplasma*, *Coccidioides*, and *Paracoccidioides* [36]. Interferon-gamma receptor 1 mutations occur in dominant and recessive forms. In the dominant form there is diminished signaling through the IFN-gamma receptor, allowing focal mycobacterial disease, commonly due to BCG or *Mycobacterium avium* complex (MAC) osteomyelitis. In the recessive form there is no IFN-gamma receptor signaling with resultant severe disseminated mycobacterial disease. Antimicrobial treatment combined with IFN-gamma cytokine therapy is typically successful in treating the infection in the dominant form, following which secondary prophylaxis prevents future infections. Once the infection is definitively treated, azithromycin 250 mg orally daily alone appears adequate prophylaxis. IFN-gamma cytokine therapy can be used to augment treatment or prophylaxis in especially complex cases. In HIV-infected individuals, primary MAC prophylaxis is usually azithromycin dosed weekly (1200 mg) or twice weekly (600 mg) or clarithromycin dosed 500 mg twice daily [1]. Whether these HIV-based prophylactic strategies would be equally effective in autosomal dominant IFN-gamma receptor defects is unknown.

For complete recessive IFN-gamma receptor defects without residual signaling, initial infection occurs typically at a younger age, is disseminated, and relapses frequently after completion of therapy, suggesting that infection is rarely eradicated. Therefore, prolonged multidrug therapies are used. Stem cell transplantation
should be considered, but is risky after infection has been established. Interferon-alpha has been used to bypass some of the IFN-gamma receptor mediated defects [37].

NF-kB essential modulator (NEMO) deficiency is also characterized by susceptibility to NTM, but the spectrum of susceptibility to other infections is much broader than that in IFN-gamma and IL-12 defects and includes bacterial, viral, and Pneumocystis susceptibility [38]. Specific antibody production is often poor and patients typically require immune globulin replacement [17].

Prophylaxis for NTM, such as azithromycin, should be strongly considered as well as prophylaxis for other bacterial infections. Since Pneumocystis susceptibility is part of the syndrome, TMP-SMX is a logical choice, but these infections are uncommon outside of early childhood. Herpes family viral infections may require secondary prophylaxis.

**Conclusion**

Prophylactic and suppressive antimicrobials are being increasingly studied. However, controlled studies are lacking for most primary immunodeficiencies, leaving practices to be guided by clinical experience as well as experience in other disease populations, such as CF and HIV. The increase in community-acquired antimicrobial resistance may alter recommended antibiotics for prophylaxis, as well as the role of immunomodulators. Disease-specific studies focused on prevention of infection and its sequelae are needed to determine specific and successful therapies.

**Acknowledgement**

The research was supported by the Intramural Research Program of the NIH, NIAID, Bethesda, MD 20892. The views expressed in this article are those of the author and do not reflect the official policy of the U.S. Government.

**References and recommended reading**

Papers of particular interest, published within the annual period of review, have been highlighted as:

● of special interest

**●● of outstanding interest**

Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 575).

1 Kaplan JE, Benson C, Holmes KH, et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep.

2 Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline for the American Heart Association Rheumatic fever, endocarditis, and Kawasaki disease committee, Council on Cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation 2007; 116:1736–1754.

3 Mattoo TK. Are prophylactic antibiotics indicated after a urinary tract infection? Curr Opin Pediatrics 2009; 21:203–206.

4 Giebink GS. Otitis media prevention: nonvaccine prophylaxis. Vaccine 2001; 19:5129–5133.

5 Healy CM, Campbell JR, Zaccaria E, Baker C. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008; 121:703–710.

6 Galler-Givati A, Fraser A, Paul M, et al. Antimicrobial prophylaxis for bacterial infections in allogeneic hematopoietic patients following chemotherapy. Cochrane Database Syst Rev 2005; 4:1–59.

7 Yong P, Orange J. Use of prophylactic antibiotics and adjunctive therapies in primary immunodeficiency diseases. Abstract, FCOIS, published in Clinical Immunology 2007; 129:539–540.

8 Winkelstein JA, Mannino MC, Johnston RB, et al. Chronic granulomatous disease: report of a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155–169.

9 Seger RA, Modern management of chronic granulomatous disease. Br J Haematol 2008; 140:255–266.

10 Margolis DH, Melnick DA, Aling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162:723–726.

11 Weening RS, Kabel P, Pijman P, Roos D. Continuous therapy with trimethoprim-sulfamethoxazole in patients with chronic granulomatous disease. J Pediatrics 1983; 1:3–127–130.

12 Gallin JI, Aling DW, Malech HL, et al. Tracbonazole to prevent fungal infections in chronic granulomatous diseases. N Engl J Med 2003; 348:2416–2422.

13 Marr KA. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Curr Opin Infect Dis 2008; 21:409–414.

14 Etzioni A. Leukocyte adhesion deficiencies: molecular basis, clinical findings, and therapeutic options. Adv Exp Med Biol 2007; 601:51–60.

15 Rosenzweig SD, Holland SM. Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 2004; 113:620–626.

16 Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Ann Rev Immunol 2009; 27:199–227.

17 Bonilla FA, Benstein L, Khan DA, Ballas ZK, et al. Practice parameters for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:51–563.

18 Tazi MR, Grigoriadou S, Carr SB, et al. Clinical Immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2006; 155:147–155.

One of the few recent antibody deficiency studies that focuses primarily on treatment.

19 Leach AJ, Morris PS. Antibiotics for the prevention of acute and chronic suppurative otitis media in children. Cochrane Database Syst Rev 2006; 4:CD004401.

20 Liston TE, Foshee WS, Pierson WD. Sulfasalazine chemoprophylaxis for frequent otitis media. Pediatrics 1983; 71:524–530.

21 Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respiratory Med 2008; 102:1494–1496.

22 Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly azithromycin in patients with bronchiectasis. Treat Respir Med 2005; 4:117–122.

23 Hagerman JK, Hancock KE, Klepser ME. Aerosolized antibiotics: a critical appraisal of their use. Exp Opin Drug Deliv 2008; 3:71–86.

24 Dobrinic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in nongenital fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39:39–44.

25 Rubin BK. Aerosolized antibiotics for noncystic fibrosis bronchiectasis. J Aerosol Med Pulmon Drug Deliv 2008; 21:71–76.

26 Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127:1420–1426.

27 Puck JM. Severe combined immunodeficiency: new advances in diagnosis and treatment. Immunol Res 2007; 38:64–67.

28 Kobynski LJ, Sullivan KE. Velocardiofacial syndrome, diGeorge syndrome; the chromosome 22q11.2 deletion syndromes. Lancet 2007; 2007:1443–1452.

29 Perez EE, Bokszczanin A, McDonald-McGinn D, et al. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (diGeorge/velocardiofacial syndrome). Pediatrics 2003; 112:635.

30 Freeman AF, Holland SM. The Hyper-IgE syndromes. Immunol Allergy Clin N Am 2008; 28:277–291.
31 Freeman AF, Kleiner DE, Nadiminti H, et al. Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol 2007; 119:1234–1240.
32 Hillard T, Edwards S, Buchdahl, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibrosis 2005; 4:215–220.
33 Wark P. Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment. Respiratory Med 2004; 98:915–923.
34 Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6:3008–3016.
35 Borro J, Sole A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin B lipid complex ( Abelcet ) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40:3090–3093.
36 Havenkamp MH, van Dissel JT, Holland SM. Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-gamma-dependent signaling. Microbes Infect 2006; 8:1157–1166.
37 Ward CM, Jyonouchi H, Kotenko SV, Smirnov SV, et al. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon-alpha 2B in a patient with complete interferon-gamma R1 deficiency. Eur J Pediatrics 2007; 166:981–985.
38 Orange JS, Jain A, Ballas ZK, et al. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol 2004; 113:725–733.